Women on semaglutide face the same gastrointestinal side effects as men at similar rates and severity, but face additional sex-specific considerations: contraceptive absorption may be affected, fertility may increase (relevant for women with PCOS), pregnancy and breastfeeding are contraindications, and menstrual cycle changes are reported anecdotally. This article covers the practical implications.
Gastrointestinal Side Effects (Same as Men)
The core side-effect profile is identical between sexes. STEP-1 trial rates in women and men were essentially the same:
| Side Effect | Approximate rate (any sex) |
|---|---|
| Nausea | ~44% |
| Diarrhea | ~30% |
| Constipation | ~24% |
| Vomiting | ~24% |
| Abdominal pain | ~20% |
| Headache | ~14% |
| Fatigue | ~11% |
Some studies suggest women report nausea slightly more often than men, but discontinuation rates are similar. Management strategies (smaller meals, hydration, slow eating) work the same way for both sexes.
Contraception and Oral Birth Control
Semaglutide slows stomach emptying, which can delay or reduce absorption of orally administered medications — including some oral contraceptives. Wegovy’s FDA prescribing information notes the potential for reduced contraceptive effectiveness with concurrent use.
Practical recommendations from many prescribers:
- Consider non-oral contraception during semaglutide use: IUD (hormonal or copper), implant, injection (Depo-Provera), patch, vaginal ring, or barrier methods
- If continuing oral contraception, discuss timing with your prescriber — taking the pill at the time of day farthest from semaglutide dosing may help
- Use back-up contraception during initial titration and after dose escalations
- Discuss with both your prescriber and gynecologist; coordinate care
The risk is theoretical rather than well-quantified — clinical trial data on contraceptive failure rates during semaglutide use are limited.
Pregnancy: A Hard Stop
Semaglutide is contraindicated in pregnancy. Animal studies show fetal harm at doses comparable to human clinical doses, including reduced fetal weight, skeletal abnormalities, and increased fetal loss.
FDA labeling recommends:
- Discontinue semaglutide at least 2 months before planned conception (due to the long 7-day half-life)
- Use effective contraception during semaglutide treatment
- If you become pregnant unexpectedly while on semaglutide, contact your prescriber immediately for guidance on stopping and monitoring
Pregnancy registries for women exposed to semaglutide are accepting data. If you’ve been exposed, your prescriber can guide enrollment to contribute to safety knowledge.
Breastfeeding
Semaglutide is not recommended during breastfeeding. Animal studies show the drug is present in breast milk, and human data are insufficient to characterize infant risk. Most prescribers recommend either stopping semaglutide or stopping breastfeeding — discuss the trade-offs based on your specific situation.
Fertility Considerations (Women with PCOS)
Women with polycystic ovary syndrome (PCOS) often have insulin resistance and irregular ovulation. Semaglutide improves insulin sensitivity and supports weight loss, both of which can restore ovulation regularity. The unintended consequence:
- Women with PCOS who previously had irregular cycles or were thought to be infertile may begin ovulating regularly
- Pregnancy can occur unexpectedly
- Effective contraception is essential during PCOS treatment with semaglutide if pregnancy is not desired
Conversely, women with PCOS seeking pregnancy may find semaglutide-induced ovulation restoration helpful — but the drug must be stopped before conception due to fetal risk. Discuss with your prescriber and reproductive endocrinologist.
Menstrual Cycle Changes
Anecdotal reports describe menstrual cycle changes on semaglutide:
- Heavier or lighter periods
- Changes in cycle length
- Spotting between periods
- Missed periods (always rule out pregnancy first)
Several mechanisms could contribute:
- Rapid weight loss reduces estrogen production from body fat (adipose tissue is a source of estrogen)
- Changes in body composition affect hormonal balance
- Improved insulin sensitivity may normalize PCOS-related cycle irregularity
- Stress and hormonal disruption from significant weight change
If cycle changes are significant or concerning, see your gynecologist. Always rule out pregnancy with a test if periods stop.
Hair Loss
Hair loss (telogen effluvium — temporary shedding from rapid weight loss) is reported by about 3 percent of weight-loss trial participants on Wegovy versus 1 percent on placebo. Women may notice this more than men due to longer hair length and different styling. The shedding is typically temporary and resolves within 6-12 months after weight stabilizes.
Mitigation strategies:
- Adequate protein intake (0.8-1.2 g/kg body weight)
- Iron-rich foods (or iron supplementation if deficient)
- Zinc, biotin, vitamin D adequacy
- Gentle hair care during shedding period
- Be patient — regrowth follows shedding
“Ozempic Face” Considerations
Rapid weight loss causes facial volume loss — a cosmetic concern often reported more visibly in women. The change is not specific to Ozempic or semaglutide; any rapid weight loss produces it. Slower titration, maintaining adequate protein, and resistance training may help preserve facial volume to some degree.
Bone Density
Rapid weight loss can reduce bone density, particularly in postmenopausal women. Combine semaglutide with weight-bearing and strength exercise to preserve bone health. Discuss bone density monitoring (DEXA scan) with your prescriber if you’re at higher risk.
The Bottom Line
Women on semaglutide experience the same gastrointestinal side effects as men. The most important sex-specific considerations are reproductive: oral contraceptive absorption may be affected (non-oral methods recommended), pregnancy is contraindicated (stop at least 2 months before conception), breastfeeding is not recommended, and PCOS patients may see restored fertility. Menstrual cycle changes and hair loss are common with rapid weight loss but typically temporary. Discuss reproductive planning, contraception, and bone health with your prescriber and gynecologist before starting semaglutide. For more on GLP-1 treatment options, see our hub.
